Medtronic Reports FY 2025 Financial Results with Increased R&D Expenses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy MDT?
Source: seekingalpha
- Financial Performance: Medtronic reported a GAAP EPS of -$1.11 for FY 2025 with revenues of $33.48 million, indicating financial challenges that could negatively impact stock performance.
- R&D Expense Increase: Research and development expenses rose to $58.2 million in 2025 from $42.8 million in 2024, a 36% increase primarily driven by costs associated with the ongoing BACKBEAT global pivotal study and the Virtue SAB program, highlighting the company's commitment to innovation.
- SG&A Expense Rise: Selling, general, and administrative expenses increased to $26.9 million in 2025 from $23.9 million in 2024, a 12% rise mainly due to higher professional fees, reflecting operational management cost pressures.
- Acquisition Activity: Medtronic's acquisition of Scientia Vascular for $550 million demonstrates strategic intent to expand its business lines and market share, despite the underwhelming debut of its diabetes unit MiniMed in trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 87.380
Low
102.00
Averages
111.76
High
120.00
Current: 87.380
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Reports FY 2025 Financial Results with Increased R&D Expenses
- Financial Performance: Medtronic reported a GAAP EPS of -$1.11 for FY 2025 with revenues of $33.48 million, indicating financial challenges that could negatively impact stock performance.
- R&D Expense Increase: Research and development expenses rose to $58.2 million in 2025 from $42.8 million in 2024, a 36% increase primarily driven by costs associated with the ongoing BACKBEAT global pivotal study and the Virtue SAB program, highlighting the company's commitment to innovation.
- SG&A Expense Rise: Selling, general, and administrative expenses increased to $26.9 million in 2025 from $23.9 million in 2024, a 12% rise mainly due to higher professional fees, reflecting operational management cost pressures.
- Acquisition Activity: Medtronic's acquisition of Scientia Vascular for $550 million demonstrates strategic intent to expand its business lines and market share, despite the underwhelming debut of its diabetes unit MiniMed in trading.
See More
Medtronic Acquires Scientia Vascular for $550 Million
- Acquisition Deal Size: Medtronic has agreed to acquire Scientia Vascular for $550 million, with potential undisclosed earn-out and milestone payments, expected to close in the first half of 2017, demonstrating Medtronic's commitment to expanding its neurovascular portfolio.
- Financial Impact Analysis: The acquisition is anticipated to be minimally dilutive to Medtronic's adjusted income per share in fiscal 2027, but is expected to become accretive thereafter, indicating a positive outlook for the company's future financial performance.
- Product Integration Advantage: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing Medtronic's product offerings and strengthening its competitive position in treating both acute ischemic and hemorrhagic strokes.
- Strategic Positioning Enhancement: Linnea Burman, Senior Vice President of Medtronic's Neurovascular business, stated that this acquisition provides a full suite of products, establishing a strong foundation that supports the company's long-term strategic development in the neuroscience sector.
See More
Medtronic Acquires Scientia Vascular for $550M
- Acquisition Overview: Medtronic has agreed to acquire neurovascular technology company Scientia Vascular for $550 million, with potential undisclosed earn-out and milestone payments, and the deal is expected to close in the first half of FY27, pending regulatory approvals.
- Employee and Operations: Scientia Vascular operates in Salt Lake City, Utah, with approximately 310 employees, and this acquisition will enhance Medtronic's competitive position in the neurovascular product portfolio, further expanding its market share.
- Financial Impact: The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27, indicating that the company can maintain financial stability while expanding its product line.
- Strategic Integration: By acquiring Scientia, Medtronic not only strengthens its technological capabilities in the neurovascular field but also prepares for future innovations and market demand changes, further solidifying its leadership position in the medical device industry.
See More
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors.
- Bargain Hunting: There are numerous bargains available, particularly those that are being purchased by company insiders.
See More
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors to find bargains.
- Insider Purchases: Many of these bargains are being purchased by company insiders, indicating potential confidence in the stocks.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Medtronic Reports FY 2025 Financial Results with Increased R&D Expenses
- Financial Performance: Medtronic reported a GAAP EPS of -$1.11 for FY 2025 with revenues of $33.48 million, indicating financial challenges that could negatively impact stock performance.
- R&D Expense Increase: Research and development expenses rose to $58.2 million in 2025 from $42.8 million in 2024, a 36% increase primarily driven by costs associated with the ongoing BACKBEAT global pivotal study and the Virtue SAB program, highlighting the company's commitment to innovation.
- SG&A Expense Rise: Selling, general, and administrative expenses increased to $26.9 million in 2025 from $23.9 million in 2024, a 12% rise mainly due to higher professional fees, reflecting operational management cost pressures.
- Acquisition Activity: Medtronic's acquisition of Scientia Vascular for $550 million demonstrates strategic intent to expand its business lines and market share, despite the underwhelming debut of its diabetes unit MiniMed in trading.
See More
Medtronic Acquires Scientia Vascular for $550 Million
- Acquisition Deal Size: Medtronic has agreed to acquire Scientia Vascular for $550 million, with potential undisclosed earn-out and milestone payments, expected to close in the first half of 2017, demonstrating Medtronic's commitment to expanding its neurovascular portfolio.
- Financial Impact Analysis: The acquisition is anticipated to be minimally dilutive to Medtronic's adjusted income per share in fiscal 2027, but is expected to become accretive thereafter, indicating a positive outlook for the company's future financial performance.
- Product Integration Advantage: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing Medtronic's product offerings and strengthening its competitive position in treating both acute ischemic and hemorrhagic strokes.
- Strategic Positioning Enhancement: Linnea Burman, Senior Vice President of Medtronic's Neurovascular business, stated that this acquisition provides a full suite of products, establishing a strong foundation that supports the company's long-term strategic development in the neuroscience sector.
See More
Medtronic Acquires Scientia Vascular for $550M
- Acquisition Overview: Medtronic has agreed to acquire neurovascular technology company Scientia Vascular for $550 million, with potential undisclosed earn-out and milestone payments, and the deal is expected to close in the first half of FY27, pending regulatory approvals.
- Employee and Operations: Scientia Vascular operates in Salt Lake City, Utah, with approximately 310 employees, and this acquisition will enhance Medtronic's competitive position in the neurovascular product portfolio, further expanding its market share.
- Financial Impact: The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27, indicating that the company can maintain financial stability while expanding its product line.
- Strategic Integration: By acquiring Scientia, Medtronic not only strengthens its technological capabilities in the neurovascular field but also prepares for future innovations and market demand changes, further solidifying its leadership position in the medical device industry.
See More
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors.
- Bargain Hunting: There are numerous bargains available, particularly those that are being purchased by company insiders.
See More
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors to find bargains.
- Insider Purchases: Many of these bargains are being purchased by company insiders, indicating potential confidence in the stocks.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
